Trial Summary
What is the purpose of this trial?This study will assess the psychosocial and behavioral impacts of receiving Alzheimer's disease genetic risk assessment incorporating APOE genotypes among Latinos in northern Manhattan. The investigators will conduct a longitudinal, community-based study with a mixed methods design. Participants will be randomized to learn about their lifetime risk of late-onset Alzheimer's disease (AD) based either on (a) Latino ethnicity and family history alone (genotype nondisclosure group), or (b) the same factors plus APOE genotype (genotype disclosure group). Responses will be evaluated at 6 weeks, 9 months, and 15 months after risk assessment. In the quantitative component of the study, the investigators will assess psychosocial outcomes, memory test performance, and health-related behaviors. In the qualitative component of the study, the investigators will investigate the lived experience of receiving personal AD risk information, using a stress and coping theoretical framework.
Eligibility Criteria
This trial is for Latinos aged 40-64 living in specific neighborhoods of northern Manhattan who have not been tested for APOE. It's not open to those with Alzheimer's, a family history of early onset Alzheimer's, or current suicidal thoughts.Inclusion Criteria
I am between 40 and 64 years old.
Exclusion Criteria
I have been diagnosed with Alzheimer's disease.
My family has a history of early Alzheimer's that can be passed down.
I am not within the required age range for the trial.
Treatment Details
The study examines the effects on Latinos of learning their genetic risk for late-onset Alzheimer's Disease. Participants will either be told their risk based on ethnicity and family history alone or with added APOE genotype information.
2Treatment groups
Experimental Treatment
Active Control
Group I: DisclosureExperimental Treatment1 Intervention
Participants will be given information about their risk of Alzheimer's disease based on Latino ethnicity, family history of Alzheimer's disease, and their APOE genotype.
Group II: Non-disclosureActive Control1 Intervention
Participants will be given information about their risk of Alzheimer's disease based on Latino ethnicity and family history of Alzheimer's disease alone.
Find a clinic near you
Research locations nearbySelect from list below to view details:
Columbia University Irving Medical CenterNew York, NY
Loading ...
Who is running the clinical trial?
Columbia UniversityLead Sponsor
National Institute on Aging (NIA)Collaborator